Stock 4579 RAQUALIA PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials RaQualia Pharma Inc.

Equities

4579

JP3967150008

Pharmaceuticals

Delayed Japan Exchange
Other stock markets
 02:00:00 2024-04-26 am EDT 		5-day change 1st Jan Change
595 JPY -1.49% Intraday chart for RaQualia Pharma Inc. +0.68% -13.52%
Mar. 26 RaQualia Pharma Inc. completed the acquisition of FIMECS, Inc. from Yusuke Tominari, Kamakanae, Nissay Capital No. 11 Investment Limited Partnership managed by Nissay Capital Co., Ltd., ANRI No. 4 Fund managed by ANRI and others. CI
Feb. 14 RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization 1 28,078 20,952 24,601 25,843 14,874 12,866
Enterprise Value (EV) 1 25,879 18,884 21,981 22,138 11,477 12,866
P/E ratio 5,158 x -34.5 x 32.5 x 35.7 x -45.9 x 14.2 x
Yield - - - - - 0.67%
Capitalization / Revenue 16.5 x 18.9 x 8.86 x 8.86 x 7.82 x 3.36 x
EV / Revenue 16.5 x 18.9 x 8.86 x 8.86 x 7.82 x 3.36 x
EV / EBITDA 226,243,739 x -57,905,633 x 28,962,610 x - - -
EV / FCF -89,237,294 x -47,686,721 x 89,611,360 x 20,658,038 x -13,747,109 x -
FCF Yield -0% -0% 0% 0% -0% -
Price to Book 6.1 x 5.24 x 5.15 x 4.71 x 2.44 x 1.75 x
Nbr of stocks (in thousands) 20,938 20,952 20,955 20,977 21,620 21,623
Reference price 2 1,341 1,000 1,174 1,232 688.0 595.0
Announcement Date 2/14/20 2/12/21 2/14/22 2/14/23 2/14/24 -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales 1 1,702 1,107 2,776 2,918 1,901 3,826
EBITDA 124.1 -361.8 849.4 - - -
EBIT 1 -15 -486 707 866 -337 1,057
Operating Margin -0.88% -43.9% 25.47% 29.68% -17.73% 27.63%
Earnings before Tax (EBT) 1 27 -527 880 851 -294 1,094
Net income 1 5 -606 755 723 -323 875
Net margin 0.29% -54.74% 27.2% 24.78% -16.99% 22.87%
EPS 2 0.2600 -28.97 36.07 34.50 -14.98 41.80
Free Cash Flow -314.6 -439.4 274.5 1,251 -1,082 -
FCF margin -18.49% -39.69% 9.89% 42.87% -56.92% -
FCF Conversion (EBITDA) - - 32.32% - - -
FCF Conversion (Net income) - - 36.36% 173.03% - -
Dividend per Share 2 - - - - - 4.000
Announcement Date 2/14/20 2/12/21 2/14/22 2/14/23 2/14/24 -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 S1 2021 Q3 2022 Q1 2022 S1 2022 Q3 2023 Q1 2023 S1 2023 Q3
Net sales 1 372 1,320 303 339 1,447 457 370 1,014 481
EBITDA - - - - - - - - -
EBIT 1 -403 314 -207 -119 551 -50 -108 -23 -85
Operating Margin -108.33% 23.79% -68.32% -35.1% 38.08% -10.94% -29.19% -2.27% -17.67%
Earnings before Tax (EBT) 1 -395 436 -193 -85 676 -3 -110 36 -73
Net income 1 -459 302 -133 -120 469 -2 -148 25 -142
Net margin -123.39% 22.88% -43.89% -35.4% 32.41% -0.44% -40% 2.47% -29.52%
EPS 2 -21.93 14.45 -6.370 -5.770 22.40 -0.1200 -6.880 1.180 -6.630
Dividend per Share - - - - - - - - -
Announcement Date 8/14/20 8/12/21 11/12/21 5/13/22 8/15/22 11/11/22 5/15/23 8/10/23 11/10/23
1JPY in Million2JPY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt - - - - - -
Net Cash position 2,199 2,068 2,620 3,705 3,397 -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow -315 -439 275 1,251 -1,082 -
ROE (net income / shareholders' equity) 0.1% -14.1% 17.2% 14.1% -5.6% 13.7%
ROA (Net income/ Total Assets) 0.47% -11.6% 18.2% 15.7% -4.46% 16.3%
Assets 1 1,058 5,225 4,149 4,595 7,236 5,368
Book Value Per Share 2 220.0 191.0 228.0 262.0 282.0 340.0
Cash Flow per Share 7.040 -23.00 42.80 41.50 -6.850 -
Capex 68 150 107 229 364 -
Capex / Sales 4% 13.56% 3.85% 7.85% 19.15% -
Announcement Date 2/14/20 2/12/21 2/14/22 2/14/23 2/14/24 -
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
595 JPY
Average target price
1,800 JPY
Spread / Average Target
+202.52%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
RAQUALIA PHARMA INC. Stock RaQualia Pharma Inc.
-13.52% 81.73M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4579 Stock
  4. Financials RaQualia Pharma Inc.